What is Cardiol Therapeutics Inc.'s (CRDL) StockRank?

MoatMap's StockRank for Cardiol Therapeutics Inc. (CRDL) is 20/100, with a Sell signal. This is a composite score combining Quality (30), Value (23), and Momentum (53) factor ranks across MoatMap's 20,000+ stock universe.

Does Cardiol Therapeutics Inc. have an economic moat?

Cardiol Therapeutics Inc. (CRDL) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Cardiol Therapeutics Inc. a buy, hold, or sell?

MoatMap's current signal for Cardiol Therapeutics Inc. (CRDL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Cardiol Therapeutics Inc. in?

Cardiol Therapeutics Inc. (CRDL) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CRDL

SELLREMOVE

Cardiol Therapeutics Inc. · Healthcare · Canada · $122M · Avg Vol: $380K/d

StockRank

P/E (TTM)

—

ROE

-174.0%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Cardiol Therapeutics is a micro-cap clinical-stage biotechnology company with high binary trial risk, failing our Terry Smith quality filter of owning established compounders with high ROIC and proven cash flows.

COMPANY DESCRIPTION

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases. The company is advancing its lead drug candidate, CardiolRx, a pharmaceutically produced cannabidiol formulation, through clinical trials for conditions like acute myocarditis, aiming to address significant unmet medical needs.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.35	-0.31	-0.36	-0.28	—
Shares	64.0M	65.4M	82.6M	100.3M	+56.5%
Debt	51,428	0.1M	0.1M	88,587	19.9%
Equity	36.8M	19.9M	17.5M	12.6M	-30.0%
Op CF	-19.2M	-17.8M	-17.7M	-16.8M	—
Inv CF	-52,725	-45,388	-15,025	-17,279	—
Fin CF	-38,063	-39,081	13.3M	11.0M	—

PRICE (1Y)-23.5%

SMA 50SMA 200

$1.04

RSI (14)

26.1

52W High

$1.71

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-191.0%2.0

ROE

-174.0%4.1

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-39.0%6.1

Piotroski

29.2

Int. Cover

—N/A

D/E Ratio

0.00x93.1

Current Ratio

4.39x67.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.8x25.0

P/FCF

—N/A

P/B

9.9x11.2

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

61%39.8

RS 6M

-5%68.5

SMA 50/200

1.13x84.7

EPS Rev 4W

-18.2%3.2

EPS Rev 12W

+45.6%89.6

EPS Improve

+29%40.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$122M

P/E (Forward)

-5.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRDL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CRDL	Cardiol Therapeutics Inc.(you)	$122M	20	SELL
OGI	Organigram Global Inc.	$138M	31	SELL
NVRS.CN	Noveris Health Sciences Inc.	$64M	23	SELL
ACB.TO	Aurora Cannabis Inc.	$180M	30	SELL
CGC	Canopy Growth Corporation	$440M	18	STRONG SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
TLRY	Tilray Brands, Inc.	$576M	7	STRONG SELL
HLS.TO	HLS Therapeutics Inc.	$100M	63	HOLD
OPTI.CN	Optimi Health Corp.	$25M	2	STRONG SELL
DB.V	Decibel Cannabis Company Inc.	$50M	60	HOLD

Peer medians: ROE -39.7% · P/E 14.3x · Gross margin 35.6%

Cardiol Therapeutics Inc. (CRDL) — Stock Score Summary

Cardiol Therapeutics Inc. (CRDL) has a MoatMap StockRank of 20/100 based on Quality (30/100), Value (23/100), and Momentum (53/100) factor scores. The current signal is SELL. Cardiol Therapeutics is a micro-cap clinical-stage biotechnology company with high binary trial risk, failing our Terry Smith quality filter of owning established compounders with high ROIC and proven cash flows.

Key Financial Metrics

Price	$1.04
Market Cap	$122M
P/E (Forward)	-5.41
Price/Book	9.94
Return on Equity	-174.0%
Return on Invested Capital	-191.0%
Debt/Equity	0.48
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-9M

Cardiol Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Cardiol Therapeutics Inc.’s (CRDL) StockRank?: MoatMap’s StockRank for Cardiol Therapeutics Inc. (CRDL) is 20/100, with a Sell signal. It is a composite of Quality (30), Value (23), and Momentum (53) factor ranks across MoatMap’s 20,000+ stock universe.
Does Cardiol Therapeutics Inc. have an economic moat?: Cardiol Therapeutics Inc. (CRDL) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cardiol Therapeutics Inc. a buy, hold, or sell?: MoatMap’s current signal for Cardiol Therapeutics Inc. (CRDL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cardiol Therapeutics Inc. in?: Cardiol Therapeutics Inc. (CRDL) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).